Our ALS-Con-201 exam materials constantly attract students to transfer their passion into progresses for the worldwide feedbacks from our loyal clients prove that we are number one in this field to help them achieve their dream in the ALS-Con-201 Exam. Though you can participate in the use of important factors, only the guarantee of high quality, to provide students with a better teaching method, thus our ALS-Con-201 study dumps bring more outstanding teaching effect.
| Section | Objectives |
|---|---|
| Topic 1: Data, Compliance, and Governance | - Compliance and Security
|
| Topic 2: Agentforce Life Sciences Consulting Fundamentals | - Industry and Regulatory Context
|
| Topic 3: Customer Engagement and Field Operations | - Engagement Execution
|
| Topic 4: Agentforce and AI Capabilities | - AI and Automation
|
>> ALS-Con-201 Exam Quick Prep <<
Fast2test has special training tools for Salesforce certification ALS-Con-201 exam, which can make you do not need to spend a lot of time and money but can get a lot of knowledge of IT technology to enhance your skills in a short time. And soon you will be able to prove your expertise knowledge and technology in IT industry. Fast2test's training courses for Salesforce Certification ALS-Con-201 Exam is developed by the study of Fast2test experts team to use their knowledge and experience.
NEW QUESTION # 102
Choose 1 option.
Cumulus Pharma wants a medical inquiry process configured where only a designated persona can assign and respond to medical inquiries.
Which configuration supports this compliance requirement?
Answer: A
Explanation:
Option B is correct because Salesforce Life Sciences Medical Inquiries uses workflow actions and persona/profile-based configuration to control who can perform specific inquiry actions, such as assigning and responding. Salesforce Help states that, before setting up Medical Inquiry, admins must make sure the required user profiles, licenses, and permission sets are in place. It also describes that medical science liaisons can assign and respond to inquiries, which confirms that these actions are intended to be controlled by role or persona.
Salesforce's Life Sciences workflow documentation also identifies workflow actions and workflow stages as part of the Medical Inquiry management setup. The Medical Inquiries workflow setup includes action buttons, workflow stages, stage operations, and conditions, allowing admins to expose or restrict actions based on configured roles and workflow state.
Option A is not the best answer because the requirement is not simply to grant a broad app permission; it is to ensure that only a designated persona can perform the assign and respond actions in the controlled Medical Inquiry process. Option C is incorrect because a custom formula field only affects display logic and does not enforce the standard workflow-action permission model. Formula-based visibility also creates compliance risk because it can hide buttons without truly governing the underlying operation. Therefore, the consultant should create workflow actions and associate those actions with the appropriate profiles in the Life Sciences Admin Console.
=========
NEW QUESTION # 103
Choose 1 option.
Cumulus Pharma wants field sales reps to see the most relevant account information directly in the aligned account list.
How should the Agentforce Life Sciences Consultant configure the account list columns after a new account list is created?
Answer: A
Explanation:
The correct answer is C because aligned account lists in Agentforce Life Sciences for Customer Engagement are configured through account list settings, where the consultant defines how the list appears to users in the mobile experience. Salesforce describes account management features in Life Sciences Cloud as enabling users to organize, prioritize, and focus on accounts through lists and filters in the Customer Engagement app. The account list configuration controls which fields appear to reps so they can quickly understand account context without opening every account record.
In this scenario, the business wants field sales reps to see the most relevant account information directly in the aligned account list. After creating the account list, the consultant should configure it as the Default list type and select up to four visible fields as columns. This gives reps a concise, mobile-friendly view of the most important account details.
Option A is incorrect because configuring the Search list affects search-result display behavior, not the aligned account list columns. It also refers to up to five account fields, which does not match the aligned account list column configuration described in the question. Option B is incorrect because assigning ownership to field sales reps does not define the visible columns in the list. Column configuration is an admin setup activity, not something resolved by record ownership. Therefore, the consultant should set the list type to Default and configure up to four visible fields.
=========
NEW QUESTION # 104
Choose 1 option.
Cumulus Pharma wants to use an external third-party provider to deliver emails sent from the Agentforce Life Sciences mobile app, rather than using the standard Salesforce email limits.
Which Apex interface should an Agentforce Life Sciences Consultant implement to manage the handoff of email operations to this third-party provider?
Answer: C
Explanation:
The correct answer is C because Salesforce Life Sciences Cloud provides the Lsc4ce.EmailQueueProcessor interface for using a third-party email service. Salesforce Help for using a third-party email service states that administrators should create a global Apex class that implements the Lsc4ce.EmailQueueProcessor interface. This interface is the supported extension point for handing off Life Sciences email operations to an external email provider instead of relying only on Salesforce's standard email sending behavior and limits.
This scenario is specifically about emails sent from the Agentforce Life Sciences mobile app. Salesforce's Field Email capability is designed to streamline compliant email creation, sending, and tracking for Life Sciences users, and the developer documentation describes LifeScienceEmail as representing a collection of sendable messages that manages creation, sending, and tracking of email communications. When an organization needs an external provider to send those emails, the custom Apex implementation must process the queued email operation and pass it to the third-party service.
Option A is incorrect because Lsc4ce.ExternalEmailHandler is not the interface identified by Salesforce for third-party email service handoff. Option B is also incorrect because Lsc4ce.MessagingService is not the documented Life Sciences email queue processing interface. Therefore, the consultant should implement Lsc4ce.EmailQueueProcessor.
=========
NEW QUESTION # 105
Choose 1 option.
Cumulus Pharma wants to ensure a sample product is visible to field sales reps during a visit.
How should the Agentforce Life Sciences Consultant configure this?
Answer: B
Explanation:
The correct answer is C because sample visibility during visits depends on the product being configured as a Life Sciences Marketable Product with an appropriate distribution method. Salesforce Help for setting up Sample Inventory Management data states that, to designate a product as a sample product, administrators create a corresponding Life Science Marketable Product record. Salesforce's Life Sciences Cloud Developer Guide for LifeSciMarketableProduct identifies distribution methods such as Drop, DropAndShip, and Ship, which define how a product is distributed to a provider.
In a provider visit, a product must be configured as marketable and available for the relevant distribution method before reps can select it for sample drop-off. If the product is meant to be handed directly to the HCP during the visit, the distribution method must include Drop. If it can be either handed off during the visit or shipped, Drop and Ship is appropriate. This setup makes the product eligible for visit-based sampling workflows.
Option A is incorrect because permissions alone do not make a specific sample product visible. Reps may have access to sampling functionality, but the product still must be configured correctly. Option B is also incorrect because profile configuration in Visit Administration is not the key product-availability control. The essential configuration is the Life Sciences Marketable Product record with the correct distribution method. Therefore, the consultant should set the distribution method to Drop or Drop and Ship.
NEW QUESTION # 106
Choose 1 option.
An Agentforce Life Sciences Consultant is asked to configure strategic distribution limits for Immunexis 50mg in a high-growth territory. The business requirement mandates that the total quantity available for the territory in the next quarter is capped, and individual field sales reps are restricted from handing off more than 50 units in a single visit.
Which administrative configuration should the consultant recommend?
Answer: A
Explanation:
Option C is correct because Territory Product Quantity Allocations are designed to manage sample product distribution at the territory level. Salesforce Help explains that territory product quantity allocations and sample limits both help manage sample distribution to HCPs, but territory product quantity allocation is used when the business needs to allocate a defined product quantity to a territory. Salesforce's setup guidance for Territory Product Quantity Allocations also states that Max Disbursement Limit Quantity is the maximum amount a sales rep can disburse in a given visit.
This directly matches the requirement. Cumulus Pharma wants to cap the total quantity of Immunexis 50mg available for a high-growth territory in the next quarter and also prevent reps from handing off more than 50 units in a single visit. A Territory Product Quantity Allocation record can store the territory-level allocated quantity, while Max Disbursement Limit Quantity enforces the per-visit disbursement cap.
Option A is incorrect because an Advanced Sample Limit Template focuses on account or provider-level sample limits, not the total allocation available to a territory. Option B is also incorrect because changing the Life Sciences Marketable Product globally would affect the entire organization, not just the high-growth territory. Therefore, the correct recommendation is to create a Territory Product Quantity Allocation record and set the per-visit max disbursement limit to 50.
=========
NEW QUESTION # 107
......
We are benefiting more and more candidates for our excellent ALS-Con-201 exam materials which is compiled by the professional experts accurately and skillfully. We are called the best friend on the way with our customers to help pass their ALS-Con-201 exam and help achieve their dreaming certification. The reason is that we not only provide our customers with valid and reliable ALS-Con-201 study questions, but also offer best service online since we uphold the professional ethical.
Reliable ALS-Con-201 Test Tutorial: https://www.fast2test.com/ALS-Con-201-premium-file.html